Atomoxetine
- Generic Name
- Atomoxetine
- Brand Names
- Strattera
- Drug Type
- Small Molecule
- Chemical Formula
- C17H21NO
- CAS Number
- 83015-26-3
- Unique Ingredient Identifier
- ASW034S0B8
- Background
Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associat...
- Indication
Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Associated Therapies
- -
Effectiveness of Antidepressant Treatment for Depression in People With Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 55
- Registration Number
- NCT00304161
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, United States
Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL
- First Posted Date
- 2006-03-06
- Last Posted Date
- 2012-04-26
- Lead Sponsor
- Monarch Medical Research
- Target Recruit Count
- 1
- Registration Number
- NCT00299234
- Locations
- 🇺🇸
Monarch Medical Research - Child and Adolescent Neurology, Norfolk, Virginia, United States
Treatment of Executive Dysfunction in Parkinson's Disease
- First Posted Date
- 2006-02-06
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 12
- Registration Number
- NCT00286949
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
Assessment of Potential Interactions Between Intravenous Cocaine and Atomoxetine - 1
- Conditions
- First Posted Date
- 2005-12-14
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 16
- Registration Number
- NCT00265265
- Locations
- 🇺🇸
Uniformed Services University of Health Science, Bethesda, Maryland, United States
Treatment of Orthostatic Intolerance
- Conditions
- Interventions
- Drug: AtomoxetineDrug: AcetazolamideDietary Supplement: MelatoninOther: NO DrugDrug: Isosorbide DinitrateRadiation: PlaceboDevice: Breathing DeviceOther: Drinking WaterProcedure: IV SalineDevice: Abdominal binderDrug: IndomethacinDrug: MidodrineDrug: MecamylamineDrug: ClonidineDrug: EntacaponeDrug: memantineDrug: ModafinilDrug: OctreotideDrug: SertralineDrug: Atomoxetine & PropranololDrug: Entacapone & PropranololDrug: PropranololDrug: Modafinil & Propranolol
- First Posted Date
- 2005-12-06
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Satish R. Raj
- Target Recruit Count
- 150
- Registration Number
- NCT00262470
- Locations
- 🇺🇸
Vanderbilt University Autonomic Dysfunction Center, Nashville, Tennessee, United States
Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety Disorder
- First Posted Date
- 2005-12-01
- Last Posted Date
- 2016-06-24
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 27
- Registration Number
- NCT00260533
Efficacy of Atomoxetine Therapy Versus Placebo for Cognitive Late Effects
- Conditions
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2022-04-01
- Lead Sponsor
- Temple University
- Registration Number
- NCT00255138
- Locations
- 🇺🇸
Temple University, Philadelphia, Pennsylvania, United States
Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children
- Conditions
- Interventions
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2023-10-02
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 93
- Registration Number
- NCT00254462
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Effect of Atomoxetine on ADHD-Related Insomnia in Children and Adolescents
- Conditions
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2006-07-07
- Lead Sponsor
- Rhode Island Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT00252278
- Locations
- 🇺🇸
Rhode Island Hospital, Providence, Rhode Island, United States
Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2019-04-24
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00218543
- Locations
- 🇺🇸
Research Foundation for Mental Hygiene, Inc., New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.